MBP and liver cancer: To compare the effectiveness of MBP-11901 and sorafenib, a major component of the primary treatment regime of clinical liver cancer, we performed cell viability assays using various liver cancer cell lines (HepG2, Hep3B, Huh-7, and PLC/PRF.5) and a normal liver cell line, AML12.